Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension

Study Purpose

Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Written informed consent.
  • - Subject with CTEPH having completed the double-blind (DB) AC-055E201/ MERIT-1 study as scheduled (i.e., who remained in the DB study up to Week 24).
  • - Females of childbearing potential must have a negative pre-treatment serum pregnancy test, be advised on appropriate methods of contraception, and agree to use 2 reliable methods of contraception.

Exclusion Criteria:

  • - Permanent discontinuation of DB study treatment due to an hepatic adverse event or liver aminotransferase abnormalities.
  • - Any known factor (e.g., drug or substance abuse) or disease (e.g., unstable psychiatric illness) that, in the opinion of the investigator, may interfere with treatment compliance or interpretation of the results, or that may influence the ability to comply with any of the study requirements.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02060721
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Actelion
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Erin McGuire
Principal Investigator Affiliation Actelion
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Belgium, China, Czechia, France, Germany, Hungary, Lithuania, Mexico, Poland, Russian Federation, Switzerland, Thailand, Turkey, Ukraine, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Chronic Thromboembolic Pulmonary Hypertension
Arms & Interventions

Arms

Experimental: Macitentan

Macitentan 10mg, oral tablet, once daily

Interventions

Drug: - Macitentan

Macitentan 10mg, oral tablet, once daily

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Leuven, Belgium

Status

Address

Leuven, ,

Beijing, China

Status

Address

Beijing, ,

Guangzhou, China

Status

Address

Guangzhou, ,

Shanghai, China

Status

Address

Shanghai, ,

Shenyang, China

Status

Address

Shenyang, ,

Wuhan, China

Status

Address

Wuhan, ,

Praha 2, Czechia

Status

Address

Praha 2, ,

Le Kremlin-Bicetre Cedex, France

Status

Address

Le Kremlin-Bicetre Cedex, ,

Paris Cedex 15, France

Status

Address

Paris Cedex 15, ,

Toulouse Cedex 9, France

Status

Address

Toulouse Cedex 9, ,

Giessen, Germany

Status

Address

Giessen, ,

Heidelberg, Germany

Status

Address

Heidelberg, ,

Würzburg, Germany

Status

Address

Würzburg, ,

Budapest, Hungary

Status

Address

Budapest, ,

Debrecen, Hungary

Status

Address

Debrecen, ,

Kaunas, Lithuania

Status

Address

Kaunas, ,

Ciudad de Mexico, Mexico

Status

Address

Ciudad de Mexico, ,

Lublin, Poland

Status

Address

Lublin, ,

Wrocław, Poland

Status

Address

Wrocław, ,

Kemerovo, Russian Federation

Status

Address

Kemerovo, ,

Moscow, Russian Federation

Status

Address

Moscow, ,

Novosibirsk, Russian Federation

Status

Address

Novosibirsk, ,

St Petersburg, Russian Federation

Status

Address

St Petersburg, ,

Tomsk, Russian Federation

Status

Address

Tomsk, ,

Zürich, Switzerland

Status

Address

Zürich, ,

Bangkok, Thailand

Status

Address

Bangkok, ,

Chiang Mai, Thailand

Status

Address

Chiang Mai, ,

Capa_Istanbul, Turkey

Status

Address

Capa_Istanbul, ,

Kyiv, Ukraine

Status

Address

Kyiv, ,

Lviv, Ukraine

Status

Address

Lviv, ,

Cambridge, United Kingdom

Status

Address

Cambridge, ,

London, United Kingdom

Status

Address

London, ,

Sheffield, United Kingdom

Status

Address

Sheffield, ,

For more information, please contact PHA at Research@PHAssociation.org and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.